Pulmonary Fibrosis
Pulmonary Fibrosis is a respiratory condition in which lung tissue becomes scarred, making it harder for the lungs to work normally. The condition is listed here as one that may be relevant when looking at supplement and interaction information, but the data provided does not include any details about symptoms, causes, or treatment.
Pulmonary fibrosis is a respiratory condition. This page provides a simple overview and related reference context.
This list shows research findings, not treatments. Nothing here replaces medical care. If you have this condition, talk to a doctor.
What may help
None of these options has good evidence yet. Best evidence first.
1 option:1 not enough evidence
Mindfulness MeditationpracticeNot enough evidence
Too few or too small studies to know if it works.
The one study found a benefit.
A review described one RCT in which online mindfulness-based interventions reduced dyspnea, with nearly half of participants reporting meaningful improvements. Disease-specific quality of life did not significantly change, and responses varied across chronic pulmonary disease phenotypes.
Open the Mindfulness Meditation page
The expert view shows every study, dose protocol and source.
What may help
Interventions recorded as helping with this condition1 listedThe best we have, but the evidence is still weak
- →PracticesMindfulness MeditationCertaintyLowSourceRCT
A review described one RCT in which online mindfulness-based interventions reduced dyspnea, with nearly half of participants reporting meaningful improvements. Disease-specific quality of life did not significantly change, and responses varied across chronic pulmonary disease phenotypes.
Who was studied
- People with a condition
Open Mindfulness MeditationStudy result
Limited evidence (1 RCT, Miranda et al.): online MBIs significantly reduced dyspnea with nearly half reporting meaningful improvements, but no significant change in disease-specific QoL (K-BILD, LCQ); review authors note heterogeneity in response across CPD phenotypes.
What to avoid
Interventions recorded as making it worseNothing in this library is currently recorded as making Pulmonary Fibrosis worse. Coverage is partial, and absence here is not evidence of safety.
How to read the evidence
Evidence tier — overall strength of the evidence for the whole compound
- StrongWell established — backed by strong, consistent human research.
- ModerateSome genuine support, but mostly from small or lower-quality studies. Promising, not proven.
- PreliminaryEarly-stage evidence — a promising hypothesis, not an established effect yet.
- LimitedVery limited evidence — treat this as a hypothesis, not proof.
- InsufficientNot enough good evidence to draw conclusions yet.
Certainty — how sure we can be that the effect is real
- Very highVery sure — strong, consistent evidence
- HighFairly sure — consistent evidence from good studies
- MediumModerately sure — new studies could change this
- LowNot sure — little or mixed evidence
- Very lowVery unsure — almost no usable evidence
Source — where the data comes from
- Meta-analysisPooled analysis of many trials — the strongest evidence
- RCTRandomized controlled trial — a strong human study design
- ClinicalA human clinical study
- Reference knowledgeFrom general health-science or pharmacology references, not a study of this exact claim
- Animal researchStudied in animals, not humans
- Community reportsAggregated user reports — anecdotal signal, not evidence
- TheoreticalMechanism-based reasoning, not yet tested
Study grade — quality of each underlying study (A best, D weakest)
- AHigh-quality — strong, consistent human trials
- BGood — solid evidence with some limitations
- CModerate — limited, small, or mixed-quality studies
- DWeak — preliminary, indirect, or animal-only
Confidence — how strongly the sources back a finding
A 0–100 score from study quality and agreement
Most supplement evidence is graded C–D. Read it as preliminary signal, not proof.
Full write-up
What is it
Pulmonary Fibrosis is a respiratory condition in which lung tissue becomes scarred, making it harder for the lungs to work normally. The condition is listed here as one that may be relevant when looking at supplement and interaction information, but the data provided does not include any details about symptoms, causes, or treatment.
Because it is a medical condition, any questions about management or whether something is appropriate should be discussed with a clinician.
Evidence-backed options
For pulmonary fibrosis, the evidence-backed options listed here are limited and early. Dihydromyricetin (DHM), Emodin, and Schisandra each have low-probability support based on animal research, which means the findings are not yet strong enough to draw firm conclusions for people.
This kind of evidence can be useful for identifying research directions, but it does not establish that these options improve pulmonary fibrosis in clinical practice. Because the available support comes from animal studies, it is best interpreted as preliminary rather than confirmed. A clinician can help place any supplement discussion in the context of the person’s overall care and the specific type and severity of disease.
What to avoid
For Pulmonary Fibrosis, the only specific avoid recommendation in the provided data is Cabergoline, which is marked as high-probability avoid based on pharmacology reference information. That means it is a notable item to discuss carefully if Cabergoline is being considered in the context of this condition.
Because the available data is limited, no other avoid items can be confirmed here. In general, decisions about what to avoid with Pulmonary Fibrosis depend on the full clinical picture, including current treatments, other health conditions, and why a substance is being considered. A clinician can help interpret whether a potential interaction or concern is relevant for a particular person.